Drivers of biodiagnostic development

David A. Giljohann & Chad A. Mirkin

The promise of point-of-care medical diagnostics — tests that can be carried out at the site of patient care — is enormous, bringing the benefits of fast and reliable testing and allowing rapid decisions on the course of treatment to be made. To this end, much innovation is occurring in technologies for use in biodiagnostic tests. Assays based on nanomaterials, for example, are now beginning to make the transition from the laboratory to the clinic. But the potential for such assays to become part of routine medical testing depends on many scientific factors, including sensitivity, selectivity and versatility, as well as technological, financial and policy factors.

Recent technological advances have markedly improved the way in which we study disease and point towards new opportunities for diagnosing disease. Researchers now have tools to observe phenomena at the level of the atom, to sequence entire genomes and to understand the molecular basis of disease. In addition, new materials, especially nanostructures, are providing novel ways of detecting markers of disease at low concentrations, in complex sample media (such as serum) and with a wide variety of assay read-outs. But many of the latest innovations are not yet being used in routine diagnostic testing, especially when point-of-care issues are important, for example when the cost of deploying an assay and training staff at the point of care is high. As biodiagnostic applications based on these new materials continue to be developed, it will be important to be conscious of the key factors that drive this process so that new tests are more likely to reach the clinic. In this Perspective, we assess the factors of assay sensitivity, selectivity and versatility, and robustness, cost and portability. We also discuss some of the materials that are allowing new assays to be designed and the consequences of developing such technologies.

Sensitivity

The diagnosis of a disease on the basis of the presence or concentration of certain biomolecules requires assays that can detect molecules of interest (or targets) sensitively. In this post-genomic era, the targets are most commonly nucleic acids or proteins. Researchers have developed two general strategies to achieve high sensitivity: target-based amplification and signal-based amplification. In target-based amplification, a recognition event triggers a catalytic process that generates more of the target being recognized or surrogates for this target. The polymerase chain reaction (PCR) is a classic example of target amplification, and modern PCR techniques can reliably detect the presence of just a few copies of a nucleic acid sequence. By contrast, in signal-based amplification, a catalytic entity is often used to increase the signal that results from a single binding event. A typical example is the enzyme-linked immunosorbent assay (ELISA), in which a target protein can be captured by an antibody and then sandwiched with a second antibody that incorporates (or is associated with) a catalytic, signal-generating entity. Certain techniques that do not involve amplification, for example single-molecule spectroscopy techniques, might seem to be sensitive; however, these types of spectroscopy typically require greater than nanomolar concentrations of the molecule to be present in order to find and probe it. Therefore, such approaches are not typically viewed as high-sensitivity methods in the context of medical diagnostics.

Target-based amplification is a more sensitive strategy than signal-based amplification and is generally considered to be a superior approach, because generating an exponential increase in target concentration leads to faster assay kinetics and pushes the thermodynamics of the probe–target capture reaction in favour of bound (detectable) target. In the short term, it seems that PCR will continue to be a benchmark for nucleic acid detection. But the instability and variability that are inherent in enzymatic processes limit its application outside an institutional setting, such as a research facility or a large central clinical lab. Another drawback to PCR is that lengthy optimization procedures are often required if several targets are to be amplified and detected at the same time, a process known as multiplexing, which is a desirable feature in the clinic, especially as panel assays (which test many disease markers simultaneously) grow in importance for diagnosing disease.

In the past decade, new materials and assays have been developed for signal–based amplification and detection, and assay sensitivities (Table 1) are now approaching those of target-based amplification. Many of these advances rely on nanoscale materials, which are attractive properties for such assays: they have unique and controllable size-dependent properties, have tunable chemical compositions, and in certain cases are chemically and physically robust structures. The tailorable properties of nanomaterials, including their high surface-to-volume ratio, mean that target-binding events are often more easily transduced into detectable signals. An example is polypeptide nanoparticles that consist of gold particles modified with biomolecules; these can be used as diagnostic probes. In one assay system, when the target binds to the biomolecules, the associated gold particles catalyse the reduction of silver, leading to a marked enhancement of signal, which can be read with a device that measures light scattered from the developed silver spots. This ‘scanoetric’ strategy allows the detection of attomolar (10⁻¹⁸) concentrations of nucleic acids and proteins in complex biological samples. Indeed, the properties of DNA-functionalized gold nanoparticles (including their optical, catalytic and binding properties) have been taken advantage of in a variety of detection methodologies, including colorimetric, fluorescent, chemiluminescent, scanoetric, surface-plasmon-resonance-based and Raman-spectroscopy-based strategies. For protein detection, certain assays using protein-modified gold nanoparticles have detection limits that are many orders of magnitude lower than those possible with a conventional technique, such as an ELISA. Detection systems based on other nanomaterials have also been evaluated. For example, biomolecule-modified carbon nanotubes and silicon nanowires are systems in which changes in electrical conductance on target binding can be translated into a spectroscopic or electrical signal. These strategies take advantage of properties of the nanomaterial, for example their conductance, to cause a measurable change in electrical signal and have resulted in detection methods of moderately high sensitivity (Table 1), which are likely to improve after further refinement.

| Department of Chemistry and International Institute for Nanotechnology, Northwestern University, 2145 Sheridan Road, Evanston, Illinois 60208, USA. |  |  | |  |
The ability to detect targets more sensitively brings its own set of challenges. Consider the example of Alzheimer’s disease. At present, markers for Alzheimer’s disease, such as amyloid-β-derived diffusible ligands, are being identified through histological studies of brain tissue. However, a definitive diagnosis based on a brain biopsy is not a viable diagnostic option. Probes that allow imaging of the brain have been developed and might lead to powerful new biodiagnostic tools, but substantial additional work is needed to identify suitable markers and to correlate their presence and concentration with the state of the disease. Importantly, some in vitro biodiagnostic tools based on new nanomaterials that have higher sensitivities than ELISAs might allow such markers to be identified in locations outside the brain, for example in the cerebrospinal fluid or blood, where the marker concentration is significantly lower (Fig. 1). But the detection of new biomarkers is just the first step towards a new treatment protocol. New biomarkers must be validated, and this process requires intensive prospective and retrospective correlational research. These studies are costly and laborious, and researchers who discover new biomarkers are often ill-equipped to test the utility of these biomarkers in a clinical setting. Indeed, even for biomarkers that have been validated in the laboratory, the process of approval by regulatory bodies such as the US Food and Drug Administration (FDA) can be long and complicated, and cannot keep pace with scientific discovery. Although these challenges present considerable barriers to the development and implementation of new biomarkers, the pay-off for doctors and patients will be enormous when it becomes possible to diagnose diseases that are not detectable with conventional biodiagnostic tools as a result of lack of sensitivity.

When it becomes possible to detect a target at extremely low concentrations, barriers to sensitivity are no longer the motivating force behind the research and are superseded by more practical concerns about how the technology can be applied. Therefore, when researchers propose a new biomarker or reach a new detection limit, it is important for the medical community to determine the clinical utility of the biomarker. Important points to consider are the meaningful concentrations of a given biomarker, and how disease states and disease cure would be defined in the context of such previously undetectable biomarkers. In addition, it should be considered whether greater sensitivity allows biomarker detection in samples that are more distant from the source of biomarker production (such as blood, breath, urine and sweat) and what concentrations are clinically relevant (Fig. 1). Clearly, analytical benchmarks, which give clinical meaning to test results, will constantly need to be evaluated and redefined when this stage of the development process is reached.

An example from research in our laboratory highlights this challenge. We recently developed an ultrahigh-sensitivity biodiagnostic system called the bio-barcode assay. This assay involves the use of gold nanoparticle probes ‘decorated’ with DNA (the barcode DNA) that is end-functionalized with antibodies specific for a target of interest. The target in the assay is sandwiched between a gold particle probe and a magnetic particle probe. Isolation of the sandwich complex in a magnetic field, followed by chemical release of the barcode DNA, results in an amplification event (each protein target is ‘traded’ for hundreds of strands of barcode DNA). The barcode DNA is then identified using a scannometric assay and the Verigene System (Nanosphere, Northbrook, Illinois), a high-sensitivity, nanotechnology-enabled biodiagnostic platform for nucleic acid detection that is commercially available and has been cleared by the FDA. Using this assay, we have achieved unparalleled levels of sensitivity for detecting a variety of targets. Indeed, we have reached the point at which new definitions of disease states may be warranted as a result of the ability to detect previously unmeasurable concentrations of antigen.

At present, for example, the clinical limit of detection of prostate-specific antigen (PSA), which is often found in increased concentrations in the serum of men with prostate cancer, is 0.1 ng/mL, using a conventional (ELISA) immunoassay. In men who have undergone radical prostatectomy (removal of the prostate gland), serum PSA concentrations are still monitored, because PSA is considered a valid marker for disease recurrence, but the main source of PSA has been removed. So it is often not possible to detect PSA in the serum of these men, because its concentration falls below 0.1 ng/mL. These patients are therefore assigned the status ‘undetectable’, and disease recurrence is monitored in terms of PSA serum concentration increases above the 0.1 ng/mL cutoff. With the development of the bio-barcode assay, it was concluded that ‘undetectable’ PSA is a limitation of current technologies: using the bio-barcode assay, PSA is measurable in the serum of nearly all patients who have had a prostatectomy, a finding that might lead to a re-evaluation of the clinical definitions of prostate cancer cure and recurrence. Accordingly, this redefinition could change the ways in which patients are monitored and treated after radical prostatectomy, and these findings present a challenge to the medical community to make appropriate use of the new technique for the benefit of their patients. In this case, many important questions remain. Can disease cure be defined as a patient having a consistent PSA concentration after prostatectomy? Can changes be made to the schedule of post-operative follow-up visits if a patient has a favourable and consistent PSA concentration? What increase in PSA concentration constitutes clinically significant disease recurrence, and how should such a patient be treated? Can new clinical trials be developed such that increasing PSA concentrations (below the conventional detection limit) are used to initiate and validate new therapy and, importantly, track an individual’s response to treatment?

This application of the bio-barcode assay highlights an interesting situation, in which it is possible to detect a disease marker at a much lower concentration than has traditionally been associated with a ‘disease-positive’ patient. The medical community now has a key role in further developing this assay and any related assays that might lead to changes in the definition of disease state, that might result in detection at an earlier stage, and that might improve the outcome for patients. Certainly, if doctors are to overcome the hurdles to the adoption of this technique and gain the advantage of more sensitive tests, the increase in sensitivity must provide meaningful information about their patients. Sceptics might ask, if the technologies for more sensitive assays are developed but no one knows what to do with the information, then why develop the tests? The answer is that enhancing sensitivity and changing analytical benchmarks are the first steps towards...
removing ‘blind spots’ in the ability to study, diagnose and treat disease, as well as in the ability to validate new therapeutics for diseases.

**Selectivity and versatility**

Not only do targets need to be detectable at low concentrations but, as a first step, they need to be identified specifically from among the numerous biomolecules present in each sample. Thus, one of the important drivers when developing new biodiagnostics is the need to recognize targets selectively, and for the next generation of biodiagnostics it will be crucial to develop methods that are versatile enough to be applicable to multiple diseases and disease states to allow their use in personalized diagnosis and medicine.

PCR is a prime example of a selective method that can be used to detect disease-specific targets present at a low copy number. PCR uses Watson–Crick base pairing to provide the selectivity needed for a nucleic acid probe to bind to a genomic DNA target and allow its subsequent amplification. PCR is also an excellent example of a technique that started as a research tool but was eventually translated into medical applications. Indeed, the versatility of PCR has allowed its use not only in clinical diagnostics but also in areas as diverse as forensics and archaeology.

Although PCR is highly selective, it lacks the versatility needed in medical diagnosis. It is clear that non-genetic targets, such as proteins, small molecules and ions, are also important biological indicators of disease. Recently, techniques such as immuno-PCR and the bio-barcode assay have been developed, and these allow proteins to be detected selectively with much greater sensitivity than in the past. Immuno-PCR, which involves the coupling of nucleic acids to antibodies and then PCR-based amplification of the nucleic acid label, provides a limit of detection comparable to the bio-barcode assay, although it is hampered by the limitations of PCR, which requires specialized assay conditions. In addition, both assays, when used for complex sample media, are limited by the selectivity of the antibodies used to capture the target. New materials can play a prominent part, at least in reducing assay complexity and in increasing the versatility of assay read-out. For example, nanoshells or noble-metal nanoparticles can be modified with agents that recognize biomolecules and used to detect proteins, elemental ions and small molecules. Assays based on such materials rely on non-enzymatic amplification of the signal with colorimetric or spectroscopic outputs. These strategies are adaptable enough to be used for recognizing many types of analyte, and as mentioned earlier the properties of the nanostructures, including their size and shape, can be manipulated, providing the needed versatility.

In the case of proteins, the issue of selectivity is considerably more challenging than for nucleic acids. Indeed, despite advances, there are many challenges still associated with identifying and making antibodies with the desired properties for binding to a target of interest. In addition, these structures are more fragile than their DNA counterparts and require special handling during storage and use. These problems are exacerbated when using antibody-labelled probes in the context of multiplexing assays. When antibodies are adsorbed on surfaces and used to assay complex sample media, scientists must contend with poor target recognition and crossreactivity with targets (that is, an antibody can bind nonspecifically to proteins in the sample). In developing next-generation biodiagnostic systems, an important step in increasing assay selectivity and versatility will be to replace antibody-based systems with chemical systems that do not have the current limitations of antibodies but have the same or greater selectivity. For example, short oligonucleotides with high selectivity and affinity, termed aptamers, provide an alternative route to highly selective recognition of targets, including small molecules and proteins.

Through multiple rounds of *in vitro* selection, aptamers can be chosen for their ability to bind to a particular target, resulting in high target selectivity. With further development, aptamers may rival antibodies in their ability to recognize targets, including proteins and small molecules. Importantly, with nucleic acids (as opposed to antibodies) as a basis for recognition, it is conceptually simpler for researchers to modify sequences and structures chemically, making them potentially suitable for signal-based amplification technologies. Finding such new robust target-recognition agents with strong binding and amplification capacities (especially for protein targets) will continue to motivate the development of biodiagnostics.

**Robustness and portability**

At present, the medical diagnostics industry is highly centralized. Diagnostic testing is based mainly in laboratories that are remote from the site of patient care and are equipped with large and complex instruments that typically require highly skilled personnel to operate them. Therefore, a major challenge in the diagnostics field is the development of robust, portable and low-cost assays that will allow disease markers to be detected reliably in places as diverse as the battlefield, the developing world, community hospitals, the doctor's office, the post office or perhaps even at home. For example, a home test may require the use of a dipstick assay test urine, whereas in a hospital a more complex assay to test blood may be warranted. Although robustness, portability and affordability are necessary features of any technological development, they are not always considered at the initial stages of assay conception and proof-of-concept demonstration. Yet inability to meet these criteria can cause some technologies to hit a dead end in their application, while other technologies accelerate past.

High-density microarrays are a good example of a new technology that generates a large amount of information per unit of time, information that can aid in disease diagnosis. Conceptually, a microarray provides a plethora of genetic information and meets the requirements for gathering data from complex sample media. A natural question to ask is what has impeded the translation of high-density microarrays to the clinic. And, although it may seem inane, why cannot such a microarray be picked up at a local pharmacy? Ultimately, the limited applicability of microarrays lies in their high cost and lack of robustness, as well as in the difficulty in interpreting and acting on the information generated from them. In this case, the ability to measure targets at the molecular level in the laboratory has outpaced the ability to translate the data into useful information for
Looking forward

The established techniques of PCR and ELISA will eventually give way to methods based on new technologies that offer comparable amplification, greater multiplexing capabilities and the prospects of lower cost and portability. New materials — in particular noble-metal nanoparticles, quantum dots, carbon nanotubes and silicon nanowires — are now redrawing analytical benchmarks for sensitivity, selectivity and versatility. When proteins and other non-nucleic-acid analytes can be detected as robustly as nucleic acids and with a technology as sensitive as PCR, the field of molecular diagnostics and medicine will be revolutionized.

When developing a new biodiagnostic test, however, there are many stakeholders, including researchers, industry, doctors, regulatory bodies and patients. Each group faces challenges with regard to both the invention and adoption of new technologies that are sensitive, selective, robust and portable. From the perspective of the researcher, the process for taking a scientific result or a breakthrough in materials development and moving it into the clinic is not straightforward. In addition, the time frame is long, and the process is expensive and not one that a conventional research laboratory is equipped to complete. This is the stage at which business enterprises have the financial and intellectual capital available to take promising technologies from the research laboratory into the clinic. However, not all promising technologies are marketable. From the perspective of the medical community, novel technologies can be a welcome addition to the doctor’s office. Nevertheless, change comes at a high cost. In addition to direct financial expenses, burdens include the time, infrastructure, regulatory issues, reimbursement considerations and experience needed to diagnose a disease on the basis of the latest technology. The disproportionate cost of adopting a technology relative to the immediate benefits to doctors and patients can prove high barriers to implementation. Regulatory agencies must find a way to keep pace with the rate of innovation and must provide incentives for generating new tests and validating disease markers. Finally, getting a technology into the hands of the patient (in a home test kit) comes with its own set of challenges, in which ease of use, cost and portability are key issues.

With such a diverse group of stakeholders with varied motivations, all of the drivers for the development of biodiagnostic assays need to be considered at each stage of development. Full understanding of these considerations is essential not only for gaining a fundamental scientific understanding of disease but also for designing and implementing innovative disease detection and treatment strategies. We predict that it will also yield the most successful biodiagnostic technologies in the future.